Loading data for CLLS — first visit, this takes a few seconds.
Cellectis S.A.
3.24 -0.08 (-2.41%)
3.10 +0.00%
- Capitalisation boursière
- $312.2M
- Volume
- 4.83K
- Prochaine publication des résultats
- Nov 13, 2026
Cellectis S.A. (CLLS) : cours, analyse et données
Valeur intrinsèque
Prévisions des analystes
Prévisions boursières →Derniers résultats
| Signalé | Écart estimé | Changement d’une année sur l’autre | |
|---|---|---|---|
| Chiffre d’affaires | $5.23M | n/a | -68.74% |
| EPS | -$0,22 | +$0,03 | 0.00% |
Métriques
- Cours acheteur
- 2.8
- Chiffre d’affaires (ttm)
- 63.8M
- Résultat net (ttm)
- -65.3M
- 2.77
- -0.64
- n/a
- -5
- P/B (ttm)
- 5.49
- P/S (ttm)
- 4.89
- Date des résultats
- Nov 13, 2026
- Cours vendeur
- 2.99
- Volume
- 4,834
- Volume moy. (20D)
- 23,003
- Ouverture
- 3.41
- Clôture précédente
- 3.32
- Fourchette du jour
- 3.21 - 3.41
- Intervalle de 52 semaines
- 2.35 - 5.48
- Analyste
- n/a
- Objectif de prix
- n/a
- Dividendes
- n/a
- Date ex-dividende
- n/a
À propos de Cellectis S.A.
Voir le profil →Cellectis S.A., a clinical stage biotechnological company, develops products based on gene-editing with a portfolio of allogeneic chimeric antigen receptor T-cells product candidates in the field of immuno-oncology and gene therapy product candidates in other therapeutic indications. The company is developing BALLI-01, to evaluate the safety, expansion, persistence, and clinical activities of lasme-cel in patients with r/r ALL; NatHaLi-01, designed to evaluate the safety, expansion, persistence, and clinical activity of eti-cel in patients with relapsed or refractory B-Cell Non-Hodgkin's Lymphoma (B-NHL). It also develops ALPHA3, targets Large B-Cell Lymphoma (LBCL); TRAVERSE, for the treatment of patients with advanced or metastatic clear cell renal cell carcinoma (RCC). In addition, the company Melanoma, for treatment of unresectable or metastatic melanoma. Cellectis S.A. was founded in 1999 and is headquartered in Paris, France.
Cellectis S.A., a clinical stage biotechnological company, develops products based on gene-editing with a portfolio of allogeneic chimeric antigen receptor T-cells product candidates in the field of immuno-oncology and gene therapy product candidates in other therapeutic indications. The company is developing BALLI-01, to evaluate the safety, expansion, persistence, and clinical activities of lasme-cel in patients with r/r ALL; NatHaLi-01, designed to evaluate the safety, expansion, persistence, and clinical activity of eti-cel in patients with relapsed or refractory B-Cell Non-Hodgkin's Lymphoma (B-NHL). It also develops ALPHA3, targets Large B-Cell Lymphoma (LBCL); TRAVERSE, for the treatment of patients with advanced or metastatic clear cell renal cell carcinoma (RCC). In addition, the company Melanoma, for treatment of unresectable or metastatic melanoma. Cellectis S.A. was founded in 1999 and is headquartered in Paris, France.
Industrie Biotechnology
Secteur Healthcare
Date d’introduction Mar 24, 2015
Employés 224
Bourse NasdaqGM
Symbole boursier CLLS
Site web https://www.cellectis.com